Prevalence of High Risk NASH patients
“We estimate at least 2 million adults have high-risk NASH in the US. Moreover, the prevalence of high-risk NASH among individuals with T2DM is higher ranging between 8.7% and 22.5%, supporting the case for coordinated case-finding and management.”
These are patients who can develop severe liver fibrosis, cirrhosis or hepatocellular carcinoma they are also at higher risk of cardiovascular and metabolic diseases as well as extrahepatic malignancies.
NAFLD is an epidemic disease if not treated will advance to NASH a deadly disease with growing prevalence. There is an urgent need for medical intervention for both conditions.
Due to heterogeneous nature of the conditions world’s well accredited KOLs believe it takes than one drug with specific MOA to treat these diseases.
Prevalence of High-risk Non-alcoholic Steatohepatitis (NASH) in the United States: Results from NHANES 2017-2018 - Clinical Gastroenterology and Hepatology